Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Alessandro Audisio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Francesco Fiorica(University of Verona), Michele Ghidini(University of Insubria), Juan Manuel O’Connor(Instituto Alexander Fleming), Michele Fiore(Università Campus Bio-Medico), María Carmen Riesco Martínez(Hospital Universitario HM Madrid), Violaine Randrian(Université de Poitiers), Marc Van den Eynde(Cliniques Universitaires Saint-Luc), Richard Adams(Velindre Cancer Centre), Karen Geboes(Universitair Ziekenhuis Leuven), Alessandro Pastorino(Ospedale Policlinico San Martino), Francesca De Felice, Jiří Tomášek(Masaryk Memorial Cancer Institute), Carolina de la Pinta(Instituto Cajal), Vaneja Velenik(Institute of Oncology Ljubljana), Roberto Moretto(Azienda Ospedaliera Universitaria Pisana), Alberto Puccini(Ospedale Policlinico San Martino), Jorge Hernando, Pètra M. Braam(Radboud University Nijmegen), Claire Antoun(Centre Hospitalier Universitaire de Besançon), Alexander Vanden Bulcke(AZ Groeninge), D. Páez López-Bravo(Hospital de Sant Pau), Alexandre Dermine(Hôpital de Jolimont), Carlos Carvalho(Champalimaud Foundation), Ahsan Javed(University of Liverpool), Demetris Papamichael(Bank of Cyprus Oncology Center), Jérôme Schwingel(cts CaritasKlinikum Saarbrücken), Ithai Waldhorn(Rambam Health Care Campus), Mehmet Artaç(Necmettin Erbakan University), Daniel Sur(Iuliu Hațieganu University of Medicine and Pharmacy), Federica Morano(Fondazione IRCCS Istituto Nazionale dei Tumori), Amélie Deleporte(Université Libre de Bruxelles), Gertjan Rasschaert(Universitair Ziekenhuis Leuven), Chiara Gallio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Ingrid Garajová(University of Parma), Matas Jakubauskas, Iva Kirac(University Hospital Centre Zagreb), Ali Shamseddine(American University of Beirut Medical Center), Audrius Dulskas(Vilnius University), Hélène Meillat(Institut Paoli-Calmettes), Michal Eid(Masaryk University), Constance Houlzé-Laroye(Centre Hospitalier Universitaire de Lille), Mauro Loi(Azienda Ospedaliero-Universitaria Careggi), Cidália Pinto(Administração Regional de Saúde de Lisboa e Vale do Tejo), Marco Messina(University of Perugia), Felix Bock(University of Rostock), Massimiliano Salati, Amélie Chau, Erika Ruíz‐García(Instituto Nacional de Cancerología)
Cited by 24
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|Annals of Oncology|2015|698
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663